Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Roche Q2 2018 Financials: “Firing on All Cylinders”

Switzerland-based Roche announced a strong second quarterly report with a 7 percent increase in group sales for the first half of 2018 and a 20 percent increase in its core EPS.

Read More »

Abbott Labs tops Q2 2018 profit estimates

Abbott Laboratories raised its 2018 full-year earnings forecast and reported a quarterly profit that beat analysts’ estimates, powered by higher sales across its businesses.

Read More »

Gilead fourth-quarter hepatitis C drug sales plummet, sees further slowdown

Gilead Sciences Inc. said fourth-quarter 2017 sales of its flagship hepatitis C drugs fell by more than half amid increased competition, and the company forecast a further slowdown for 2018.

Read More »

Allergan’s migraine drug succeeds in key study

Allergan Plc reported better-than-expected fourth-quarter 2017 profit and announced positive data on one of the two migraine treatments it is developing.

Read More »

Novo Nordisk warns of U.S. legislation

Drugmaker Novo Nordisk warned that draft legislation in some U.S. states to make pricing more transparent could impact business in the company’s largest market.

Read More »

Pfizer beats Q3 2017 profit estimates

Pfizer Inc.’s third-quarter profit beat market estimates and the company raised its full-year 2017 earnings forecast.

Read More »

New cancer drugs help J&J top profit estimates

Johnson & Johnson reported a higher-than-expected third-quarter 2017 profit and raised its full-year forecast as the company gained from strong sales of its new cancer drugs.

Read More »

Medtronic misses revenue estimates, shares dip

Medical device maker Medtronic Plc reported Q1 fiscal 2018 revenue fell short of analysts’ estimates, hurt by lower sales in its diabetes-related device business.

Read More »

Mylan cuts forecasts on delays in new drugs

Mylan NV said that delays in launching key new drugs and eroding prices for generics in the United States will hurt its profitability in 2017 and 2018.

Read More »

AbbVie’s profit beats analysts’ expectations

U.S. drugmaker AbbVie Inc. reported Q2 2017 earnings that edged past analysts’ expectations, helped by robust demand for the company’s flagship RA drug Humira.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom